infectious disease

Infections such as HIV, COVID and bacterial infections: drugs, vaccines and diagnostics for them.

Theme · 9 companies · 2 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ARMP Armata Pharmaceuticals, Inc.

    In development“We remain committed to our mission to evaluate phage-based therapeutics in randomized controlled clinical trials that evaluate safety and efficacy required to support potential regulatory approval and commercialization of our phage products as alternatives to traditional antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • BRKR Bruker

    Sells it“Our Genotype and Fluorotype molecular diagnostics (“MDx”) kits enable a culture-free detection and analysis of microbes and viruses directly from patient samples with a special focus on tuberculosis, HIV viral load, viral hepatitis and sexually transmitted diseases.”

    Latest 8-KLeadership change ·

    Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

  • GILD Gilead Sciences

    Sells it“Gilead depends substantially on HIV treatment and prevention products.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.

    • Revenue$8.3BYoY +6.8%
    • Net income$2.4BYoY −20.4%
  • INVA Innoviva, Inc.

    Sells it 24%, $98.5M a year“Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:”

    Latest 10-QQ3 FY2026Positive ·

    XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings

    • Revenue$106.1MYoY −1.6%
    • Net income−$73.9Mvs $89.9M year ago
  • JNJ Johnson & Johnson

    Sells it“Infectious Diseases (e.g., HIV/AIDS)”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • MRK Merck & Co.

    Sells it 20%, $12.8B a year“Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • MRNA Moderna

    Sells it“COVID vaccine sales were $1.680B for 9M 2026 versus $1.168B; RSV sales were $39M versus $4M.”

    Latest 8-KPositiveDebt financing ·

    Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.

  • PFE Pfizer

    Sells it“Our R&D primarily focuses on our main therapeutic areas, which are oncology, internal medicine (including cardiometabolic, weight management and migraine), vaccines (with a pipeline focus on infectious diseases with significant unmet medical need) and inflammation and immunology.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • SDGR Schrödinger, Inc.

    Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%

Feedback